• Press Release

Mount Sinai Researcher Receives Prestigious Award From the Asbestos Disease Awareness Organization

Andrea Wolf, MD, recognized for lifetime achievements in advancing understanding of mesothelioma

  • New York, NY
  • (January 03, 2023)

Andrea Wolf, MD, Director of the New York Mesothelioma Program at the Mount Sinai Health System, has received the prestigious 2022 Irving J. Selikoff Lifetime Achievement Award from the Asbestos Disease Awareness Organization.

The award is presented annually to an individual or organization for their dedication to increasing awareness and prevention efforts to eliminate asbestos-related diseases. The award is named in honor of Dr. Selikoff, who first discovered the relationship between asbestos and mesothelioma at Mount Sinai, establishing a legacy of expertise in this disease, occupational medicine, and environmental medicine.

Mesothelioma is a type of lung cancer, and those who are most at risk of developing mesothelioma are people who have had long-term exposure to asbestos, such as construction workers, pipefitters, and shipyard workers. It takes many years for mesothelioma to develop following exposure to asbestos.

“Dr. Wolf has been integral in the development of lung cancer screening and nodule follow-up programs for underserved patients at Mount Sinai,” said Raja M. Flores, MD, Chair of Thoracic Surgery, and the Steven and Anne Ames Professor in Thoracic Surgery, at the Icahn School of Medicine at Mount Sinai. “She has received accolades from patients and colleagues for helping to provide the highest level of care to minority and socioeconomically disadvantaged patients. Her skills, knowledge, and judgment, combined with a passion for her patients and their families, have gained her a reputation for unparalleled clinical excellence.”

An outstanding surgeon and clinician, Dr. Wolf focuses her research on malignant pleural mesothelioma, a rare tumor that involves the lining of the lungs and chest wall. Drawing on her expertise in statistical analysis, Dr. Wolf has conducted database studies to investigate outcomes, as well as racial and gender disparities, among patients with mesothelioma and other thoracic malignancies.

She has distinguished herself academically by authoring more than 70 peer-reviewed publications, 20 book chapters, and 25 abstracts, and delivering more than 45 presentations and invited talks.  In 2020, Dr. Wolf and the New York Mesothelioma Program team received the International Association for the Study of Lung Cancer Care Team Award.


About the Mount Sinai Health System

Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.

As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.

Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.